Product Description
Acarbose is used (with diet only or diet and other medications) to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood) . Acarbose works by slowing the action of certain chemicals that break down food to release glucose (sugar) into your blood. Slowing food digestion helps keep blood glucose from rising very high after meals.
Mechanisms of Action: GAA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Korea | Lebanon | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovenia | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Type 2 Diabetes
Phase 2: Obesity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Study Exploring the Supportive effect of Acarbose in weight Management - SESAM | P2 |
Active, not recruiting |
Obesity |
2023-10-15 |
|
| CTR20230505 | P1 |
Completed |
Type 2 Diabetes |
2023-03-29 |
|
| 2019-004545-32 | P2 |
Active, not recruiting |
Obesity |
2021-10-07 |
|
| CTR20220610 | P1 |
Not yet recruiting |
Type 2 Diabetes |
None |